Frederick Lief Ruberg, MD – Chief, Cardiovascular Medicine
Professor, Medicine
Biography
Frederick L. Ruberg, MD is the Thomas J. Ryan Professor of Cardiovascular Medicine and Professor of Radiology at Boston University (BU) Chobanian & Avedisian School of Medicine and Chief, Section of Cardiovascular Medicine at Boston Medical Center (BMC). Dr. Ruberg attended the University of Pennsylvania Perelman School of Medicine, completed internal medicine training at Brigham and Women’s Hospital, cardiovascular disease fellowship at Boston Medical Center/Boston University School of Medicine, followed by a fellowship in cardiovascular magnetic resonance (CMR) imaging at Beth Israel Deaconess Medical Center in Boston. Committed to research mentorship, he co-directs Workforce Development for the Boston University Clinical and Translational Science Institute (CTSI) and serves as Senior Associate Editor of Circulation: Cardiovascular Imaging. Dr. Ruberg is a Fellow of the American Heart Association and a member of the Association of University Cardiologists. His clinical and research expertise primarily involves cardiac imaging and infiltrative heart disease focused on improving the recognition and care of patients with cardiac amyloidosis, particularly that owing to ATTR and the hereditary genetic TTR variant Val122Ile (or V142I). He is an investigator on numerous NIH-funded awards including co-PI of the $7.2m NHLBI-funded Screening for Cardiac Amyloidosis with Nuclear Imaging (SCAN-MP, R01 HL139671) study. An active clinical cardiologist at the BU Amyloidosis Center, he has also contributed and co-directed numerous collaborative clinical guidelines initiatives, including mostly recently the 2023 the ACC Expert Consensus Decision Pathway document on The Comprehensive Multidisciplinary Care of Patient with Cardiac Amyloidosis. Dr. Ruberg has been recognized with mentorship (2017) and citizenship (2022) awards from the BU Department of Medicine.
Other Positions
- Professor, Radiology, Boston University Chobanian & Avedisian School of Medicine
- Member, Whitaker Cardiovascular Institute, Boston University
- Member, Amyloidosis Center, Boston University
- Program Director, Pilot Translational & Clinical Studies Program, Clinical and Translational Science Institute, Boston University Chobanian & Avedisian School of Medicine
Education
- University of Pennsylvania School of Medicine, MD
- Haverford College, BA
Classes Taught
Publications
- Published on 2/20/2025
Dorbala S, Adigun R, Alexander KM, Brambatti M, Cuddy SAM, Dispenzieri A, Dunnmon P, Emdin M, Abou Ezzeddine OF, Falk RH, Fontana M, Grodin JL, Guthrie S, Jerosch-Herold M, Hofling AA, Hsu K, Lin G, Masri A, Maurer MS, Mittmann C, Prasad K, Quarta CC, Race JM, Rajendran JG, Ruberg FL, Sachdev V, Sanchorawala V, Signorovitch J, Sirac C, Soman P, Sorensen J, Sperry BW, Stephens AW, Stockbridge NL, Vest J, Wall JS, Wechalekar A, Welsh C, Lousada I. Development of Imaging Endpoints for Clinical Trials in AL and ATTR Amyloidosis: Proceedings of the Amyloidosis Forum. JACC Cardiovasc Imaging. 2025 Feb 20. PMID: 39985507.
Read at: PubMed - Published on 1/22/2025
Cheng RK, Leedy D, Ruberg FL. Can Outpatient Worsening Heart Failure Serve as an Endpoint in Clinical Trials of Transthyretin Amyloidosis? J Am Coll Cardiol. 2025 Feb 25; 85(7):762-765. PMID: 39846939.
Read at: PubMed - Published on 11/23/2024
Chan N, Einstein AJ, Teruya S, Rodriguez C, Helmke S, Cuomo M, Santana D, Castillo M, Smiley D, Sabogal N, Lamour S, Winburn M, Fine D, de Freitas C, Kattan CG, Miller EJ, Maurer MS, Ruberg FL. The Impact of Active Ascertainment on Sex-Specific Differences in the Prevalence and Phenotype of Transthyretin Cardiac Amyloidosis: The Screening for Cardiac Amyloidosis With Nuclear Imaging in Minority Populations Study. Am J Cardiol. 2025 Feb 15; 237:60-64. PMID: 39581521.
Read at: PubMed - Published on 9/4/2024
Clerc OF, Vijayakumar S, Cuddy SAM, Bianchi G, Canseco Neri J, Taylor A, Benz DC, Datar Y, Kijewski MF, Yee AJ, Ruberg FL, Liao R, Falk RH, Sanchorawala V, Dorbala S. Functional Status and Quality of Life in Light-Chain Amyloidosis: Advanced Imaging, Longitudinal Changes, and Outcomes. JACC Heart Fail. 2024 Dec; 12(12):1994-2006. PMID: 39243245.
Read at: PubMed - Published on 8/7/2024
Urina-Jassir M, Teruya S, Blaner WS, Brun PJ, Prokaeva T, Tsai FJ, Kelly JW, Maurer MS, Ruberg FL. Differential Association of Transthyretin Stability with Variant and Wild-Type Transthyretin Amyloid Cardiomyopathy: The SCAN-MP Study. JACC Heart Fail. 2024 Dec; 12(12):2113-2115. PMID: 39115519.
Read at: PubMed - Published on 7/10/2024
Clerc OF, Datar Y, Cuddy SAM, Bianchi G, Taylor A, Benz DC, Robertson M, Kijewski MF, Jerosch-Herold M, Kwong RY, Ruberg FL, Liao R, Di Carli MF, Falk RH, Dorbala S. Prognostic Value of Left Ventricular 18F-Florbetapir Uptake in Systemic Light-Chain Amyloidosis. JACC Cardiovasc Imaging. 2024 Aug; 17(8):911-922. PMID: 39001731.
Read at: PubMed - Published on 7/10/2024
Clerc OF, Cuddy SAM, Jerosch-Herold M, Benz DC, Katznelson E, Canseco Neri J, Taylor A, Kijewski MF, Bianchi G, Ruberg FL, Di Carli MF, Liao R, Kwong RY, Falk RH, Dorbala S. Myocardial Characteristics, Cardiac Structure, and Cardiac Function in Systemic Light-Chain Amyloidosis. JACC Cardiovasc Imaging. 2024 Nov; 17(11):1271-1286. PMID: 39001736.
Read at: PubMed - Published on 6/10/2024
Thel MC, Cochran JD, Teruya S, Hayashi O, Xie CR, Srinivasan AR, Chavkin NW, Arai Y, Sano S, Mirabal Santos A, De Los Santos J, Fine D, Sabogal N, Ullah I, Helmke S, Rodriguez C, Prokaeva T, Foster RH, Spencer BH, Izumiya Y, Maurer MS, Walsh K, Ruberg FL. Mosaic Loss of the Y Chromosome Is Enriched in Patients With Wild-Type Transthyretin Cardiac Amyloidosis and Associated With Increased Mortality. Circ Heart Fail. 2024 Aug; 17(8):e011681. PMID: 38853760.
Read at: PubMed - Published on 6/4/2024
Maurer MS, Miller EJ, Ruberg FL. Addressing Health Disparities-The Case for Variant Transthyretin Cardiac Amyloidosis Grows Stronger. JAMA. 2024 Jun 04; 331(21):1809-1811. PMID: 38734953.
Read at: PubMed - Published on 6/4/2024
Maurer MS, Soman P, Hernandez A, Garcia-Pavia P, Signorovitch J, Wei LJ, Hanna M, Ruberg FL, Kittleson M, Kazi D, Dorbala S, Hsu K, Lousada I, Adigun R, Dunnmon P, Kelly J, Gillmore J. Advancing Transthyretin Amyloidosis Drug Development in an Evolving Treatment Landscape: Amyloidosis Forum Meeting Proceedings. Adv Ther. 2024 Jul; 41(7):2723-2742. PMID: 38833142.
Read at: PubMed
View 138 more publications: View full profile at BUMC